122 related articles for article (PubMed ID: 38940324)
1. Improved detection of cystic fibrosis by the California Newborn Screening Program for all races and ethnicities.
McGarry ME; Sciortino S; Graham S; Bishop T; Gibb ER
Pediatr Pulmonol; 2024 Jun; ():. PubMed ID: 38940324
[TBL] [Abstract][Full Text] [Related]
2. Detection of disease-causing CFTR variants in state newborn screening programs.
McGarry ME; Ren CL; Wu R; Farrell PM; McColley SA
Pediatr Pulmonol; 2023 Feb; 58(2):465-474. PubMed ID: 36237137
[TBL] [Abstract][Full Text] [Related]
3. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
[TBL] [Abstract][Full Text] [Related]
4. Variation in cystic fibrosis newborn screening algorithms in the United States.
Rehani MR; Marcus MS; Harris AB; Farrell PM; Ren CL
Pediatr Pulmonol; 2023 Mar; 58(3):927-933. PubMed ID: 36507555
[TBL] [Abstract][Full Text] [Related]
5. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years.
Skov M; Baekvad-Hansen M; Hougaard DM; Skogstrand K; Lund AM; Pressler T; Olesen HV; Duno M
Pediatr Pulmonol; 2020 Feb; 55(2):549-555. PubMed ID: 31682332
[TBL] [Abstract][Full Text] [Related]
6. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine.
Januska MN; Marx L; Walker PA; Berdella MN; Langfelder-Schwind E
J Genet Couns; 2020 Aug; 29(4):607-615. PubMed ID: 32227567
[TBL] [Abstract][Full Text] [Related]
7. Severe lung disease in children with cystic fibrosis missed in newborn screening.
Baldwin K; Barker EM; Carayannopoulos M; Farrell PM; Zanni R; Scanlin TF
Pediatr Pulmonol; 2024 Jan; 59(1):163-168. PubMed ID: 37888495
[TBL] [Abstract][Full Text] [Related]
8. Cystic fibrosis newborn screening: the importance of bloodspot sample quality.
Doull I; Course CW; Hanks RE; Southern KW; Forton JT; Thia LP; Moat SJ
Arch Dis Child; 2021 Mar; 106(3):253-257. PubMed ID: 32859613
[TBL] [Abstract][Full Text] [Related]
9. Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor.
Patel P; Yeley J; Brown C; Wesson M; Lesko BG; Slaven JE; Chmiel JF; Jain R; Sanders DB
Int J Neonatal Screen; 2023 Feb; 9(1):. PubMed ID: 36975847
[TBL] [Abstract][Full Text] [Related]
10. Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis.
Ooi CY; Sutherland R; Castellani C; Keenan K; Boland M; Reisman J; Bjornson C; Chilvers MA; van Wylick R; Kent S; Price A; Mateos-Corral D; Hughes D; Solomon M; Zuberbuhler P; Brusky J; Durie PR; Ratjen F; Gonska T
BMC Pediatr; 2019 Oct; 19(1):369. PubMed ID: 31640630
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.
Nshimyumukiza L; Bois A; Daigneault P; Lands L; Laberge AM; Fournier D; Duplantie J; Giguère Y; Gekas J; Gagné C; Rousseau F; Reinharz D
J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947
[TBL] [Abstract][Full Text] [Related]
12. A survey of newborn screening for cystic fibrosis in Europe.
Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
Parad RB; Comeau AM
J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
[TBL] [Abstract][Full Text] [Related]
14. Diagnosing cystic fibrosis in newborn screening in Poland - 15 years of experience.
Sands D; Zybert K; Mierzejewska E; Ołtarzewski M
Dev Period Med; 2015; 19(1):16-24. PubMed ID: 26003066
[TBL] [Abstract][Full Text] [Related]
15. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols.
Gregg RG; Wilfond BS; Farrell PM; Laxova A; Hassemer D; Mischler EH
Am J Hum Genet; 1993 Mar; 52(3):616-26. PubMed ID: 7680526
[TBL] [Abstract][Full Text] [Related]
16. Screening for cystic fibrosis in New York State: considerations for algorithm improvements.
Kay DM; Maloney B; Hamel R; Pearce M; DeMartino L; McMahon R; McGrath E; Krein L; Vogel B; Saavedra-Matiz CA; Caggana M; Tavakoli NP
Eur J Pediatr; 2016 Feb; 175(2):181-93. PubMed ID: 26293390
[TBL] [Abstract][Full Text] [Related]
17. Current Status of Genetic Diagnosis Laboratories and Frequency of Genetic Variants Associated with Cystic Fibrosis through a Newborn-Screening Program in Turkey.
Bozdogan ST; Mujde C; Boga I; Sonmezler O; Hanta A; Rencuzogullari C; Ozcan D; Altintas DU; Bisgin A
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33572515
[TBL] [Abstract][Full Text] [Related]
18. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
[TBL] [Abstract][Full Text] [Related]
19. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
[TBL] [Abstract][Full Text] [Related]
20. Performance of a Three-Tier (IRT-DNA-IRT) Cystic Fibrosis Screening Algorithm in British Columbia.
Sinclair G; McMahon V; Schellenberg A; Nelson TN; Chilvers M; Vallance H
Int J Neonatal Screen; 2020 Jun; 6(2):46. PubMed ID: 33073036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
